Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847935 | 0.99 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1852973 | 0.93 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1852776 | 0.93 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1852886 | 0.93 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1850864 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1848341 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1852017 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1852019 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL1848345 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 | |
| SCHEMBL12661727 | 0.90 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121419-B1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA SL (ES) | 2024-08-14 | — | — | EP | claimed |
| EP-3592734-B1 | AMINE SALT OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA SL (ES) | 2021-05-19 | — | — | EP | claimed |
| EP-2197860-B1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2011-05-25 | — | — | EP | claimed |
| EP-4199922-B1 | (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID FOR USE IN THE TREATMENT OF AIRWAY DISEASES | PALOBIOFARMA SL (ES) | 2024-09-25 | — | — | EP | disclosed |
| EP-4121419-B1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA SL (ES) | 2024-08-14 | — | — | EP | disclosed |
| EP-4199922-A1 | (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES | Palobiofarma, S.L. (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-20230183195-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA, S.L. (ES) | 2023-06-15 | — | — | US | disclosed |
| EP-4121419-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | Palobiofarma, S.L. (ES) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121419-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | Palobiofarma, S.L. (ES) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121419-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | Palobiofarma, S.L. (ES) | 2023-01-25 | — | — | EP | disclosed |
| EP-3957308-A1 | (1R,3S)-3-((5-CYANO-4-PHENYLTHIAZOL-2-YL)CARBAMOYL)CYCLOPENTANE-1-CARBOXYLIC ACID AND DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF AIRWAY DISEASES | Palobiofarma, S.L. (ES) | 2022-02-23 | — | — | EP | disclosed |
| WO-2021185748-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA, S.L. (ES) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021185748-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA, S.L. (ES) | 2021-09-23 | — | — | WO | disclosed |
| EP-3882240-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | Palobiofarma, S.L. (ES) | 2021-09-22 | — | — | EP | disclosed |
| EP-3882240-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCABAMOYL)CYCLOPENTANE CARBOXYLIC ACID | Palobiofarma, S.L. (ES) | 2021-09-22 | — | — | EP | disclosed |
| EP-3592734-B1 | AMINE SALT OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA SL (ES) | 2021-05-19 | — | — | EP | disclosed |
| EP-3592734-B1 | AMINE SALT OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | PALOBIOFARMA SL (ES) | 2021-05-19 | — | — | EP | disclosed |
| US-10583127-B2 | Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | PALOBIOFARMA, S.L. (ES) | 2020-03-10 | — | — | US | disclosed |
| US-8410282-B2 | Compounds as adenosine A1 receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10583127-B2 | Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-20230183195-A1 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-20100311703-A1 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.